Therapeutic peptidomimetic strategies for autoimmune diseases: costimulation blockade
- PMID: 15885118
- DOI: 10.1111/j.1399-3011.2005.00256.x
Therapeutic peptidomimetic strategies for autoimmune diseases: costimulation blockade
Abstract
Cognate interactions between immune effector cells and antigen-presenting cells (APCs) govern immune responses. Specific signals occur between the T-cell receptor peptide and APCs and nonspecific signals between pairs of costimulatory molecules. Costimulation signals are required for full T-cell activation and are assumed to regulate T-cell responses as well as other aspects of the immune system. As new discoveries are made, it is becoming clear how important these costimulation interactions are for immune responses. Costimulation requirements for T-cell regulation have been extensively studied as a way to control many autoimmune diseases and downregulate inflammatory reactions. The CD28:B7 and the CD40:CD40L families of molecules are considered to be critical costimulatory molecules and have been studied extensively. Blocking the interaction between these molecules results in a state of immune unresponsiveness termed 'anergy'. Several different strategies for blockade of these interactions are explored including monoclonal antibodies (mAbs), Fab fragments, chimeric, and/or fusion proteins. We developed novel, immune-specific approaches that interfere with these interactions. Using experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis mediated by central nervous system (CNS)-specific T-cells, we developed a multi-targeted approach that utilizes peptides for blockade of costimulatory molecules. We designed blocking peptide mimics that retain the functional binding area of the parent protein while reducing the overall size and are thus capable of blocking signal transduction. In this paper, we review the role of costimulatory molecules in autoimmune diseases, two of the most well-studied costimulatory pathways (CD28/CTLA-4:B7 and CD40:CD40L), and the advantages of peptidomimetic approaches. We present data showing the ability of peptide mimics of costimulatory molecules to suppress autoimmune disease and propose a mechanism for disease suppression.
Similar articles
-
A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.J Mol Biol. 2005 Mar 11;346(5):1299-311. doi: 10.1016/j.jmb.2004.12.052. Epub 2005 Jan 22. J Mol Biol. 2005. PMID: 15713482
-
Role of costimulatory pathways in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis.J Allergy Clin Immunol. 2003 Nov;112(5):837-49; quiz 850. doi: 10.1016/j.jaci.2003.08.025. J Allergy Clin Immunol. 2003. PMID: 14610467 Review.
-
Role of costimulatory molecules in autoimmunity.Rev Immunogenet. 2000;2(1):74-80. Rev Immunogenet. 2000. PMID: 11324695 Review.
-
Lymphocyte costimulatory receptors in renal disease and transplantation.J Nephrol. 2002 Jan-Feb;15(1):7-16. J Nephrol. 2002. PMID: 11936430 Review.
-
Targeting costimulatory pathways for tumor immunotherapy.Int Rev Immunol. 2007 May-Aug;26(3-4):161-96. doi: 10.1080/08830180701365941. Int Rev Immunol. 2007. PMID: 17558743 Review.
Cited by
-
A CD40-targeted peptide controls and reverses type 1 diabetes in NOD mice.Diabetologia. 2014 Nov;57(11):2366-73. doi: 10.1007/s00125-014-3342-5. Epub 2014 Aug 8. Diabetologia. 2014. PMID: 25104468 Free PMC article.
-
CD40 and autoimmunity: the dark side of a great activator.Semin Immunol. 2009 Oct;21(5):293-300. doi: 10.1016/j.smim.2009.05.012. Semin Immunol. 2009. PMID: 19595612 Free PMC article. Review.
-
HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells.Oncoimmunology. 2014 Dec 21;3(11):e956012. doi: 10.4161/21624011.2014.956012. eCollection 2014 Nov. Oncoimmunology. 2014. PMID: 25941588 Free PMC article.
-
The apoptotic pathway as a therapeutic target in sepsis.Curr Drug Targets. 2007 Apr;8(4):493-500. doi: 10.2174/138945007780362764. Curr Drug Targets. 2007. PMID: 17430119 Free PMC article. Review.
-
Inhibition of CD40-CD154 costimulatory pathway by a cyclic peptide targeting CD154.J Mol Med (Berl). 2009 Feb;87(2):181-97. doi: 10.1007/s00109-008-0416-1. Epub 2008 Nov 5. J Mol Med (Berl). 2009. PMID: 18985310
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous